Rituximab for the treatment of CD20-positive peripheral T-cell lymphoma, unspecified

Leukemia Research

Volumn 33, Issue 6, 2009, Pages

  Hirata, Yuji ^a   Yokote, Taiji ^a   Kobayashi, Kichinosuke ^a   Nakayama, Shoko ^a   Miyoshi, Takuji ^a   Akioka, Toshikazu ^a   Hara, Satoshi ^a   Tsuji, Motomu ^a   Takubo, Takayuki ^b   Hanafusa, Toshiaki ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

^b Laboratory Medicine   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; BICARBONATE; CD20 ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FUROSEMIDE; METHYLPREDNISOLONE; PREDNISOLONE; RITUXIMAB; VINCRISTINE;

AGED; ANAMNESIS; ANTIGEN EXPRESSION; BLOOD EXAMINATION; BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; CASE REPORT; CHROMOSOME ANALYSIS; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DYSPNEA; FEMALE; HUMAN; HUMAN TISSUE; LETTER; LYMPHADENOPATHY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; T CELL LYMPHOMA; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR LYSIS SYNDROME;

AGED; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; LYMPHOMA, T-CELL;

EID: 63349098316     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2008.09.034     Document Type: Letter

References (31)

1. Aisenberg A., Wilkes B., and Jacobson J. Different T-cell receptor gene configurations in T-cell neoplasms and acute lymphocytic leukemia. Cancer Res 51 (1991) 6103-6109
2. Aisenberg A., Wilkes B., and Jacobson J. Immunogloblin gene arrangements in adult non-Hodgkin's lymphoma. Am J Med 82 (1987) 738-747
3. Ralfkiaer E., Müller-Hermelink H.K., and Jaffe E.S. Peripheral T-cell lymphoma, unspecified. In: Jaffe E.S., Harris N.L., Stein H., and Vardin J.W. (Eds). WHO classification of tumors of hematopoietic and lymphoid tissues (2001), IARC Press, Lyon 227-229
4. Greene F.L., Page D.L., and Fleming I.D. AJCC cancer staging manual. 6th edition (2002), Springer-Verlag, Philadelphia
5. Gallamini A., Stelitano C., Calvi R., et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood 103 (2004) 2474-2479
6. McKelvey E.M., Gottlieb J.A., Wilson H.E., et al. Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer 38 (1976) 1484-1493
7. Lister T.A., Crowther D., Sutcliffe S.B., et al. Report of a committee converted to discuss the evaluation and staging of patients with Hodgkin's disease: Costwolds meeting. J Clin Oncol 7 (1989) 16-30
8. Velasquez W.S., McLaughlin P., Tucker S., et al. ESHAP an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol 12 (1994) 1169-1176
9. McLaughlin P., Grillo-Lopez A.J., Link B.K., et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 8 (1998) 2825-2833
10. Keating M.J., Flinn I., Jai V., et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 99 (2002) 3554-3561
11. Smith M.R. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 22 (2003) 7359-7368
12. Creutzig U., Harbott J., Sperling C., et al. Clinical significance of surface antigen expression in children with acute myeloid leukemia: results of study AML-BFM-87. Blood 86 (1995) 3097-3108
13. Lonard J.P., and Goldenberg D.M. Preclinical and clinical evaluation of epratuzumab (anti-CD22 IgG) in B-cell malignancies. Oncogene 26 (2007) 3704-3713
14. In: Jaffe E.S., Harris N.L., Stein H., and Vardin J.W. (Eds). WHO classification of tumors of hematopoietic and lymphoid tissues (2001), IARC Press, Lyon
15. Rawstron A.C., Laycock-Brown G., Hale G., et al. CD52 expression patterns in myeloma and the applicability of alemtuzumab therapy. Haematologica 91 (2006) 1577-1578
16. Tibes R., Keating M.J., Ferrajoli A., et al. Activity of patients with CD52-positive acute leukemia. Cancer 15 (2006) 2645-2651
17. Treon S.P., Pilarski L.M., Belch, et al. CD20-directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applications. J Immunother 25 (2002) 72-81
18. Zwaan ChM, Reinhardt D., Corbacioglu S., et al. Gemtuzumab ozogamicin: first clinical experiences in children with relapsed/refractory acute myeloid leukemia treated on compassionate-use basis. Blood 15 (2003) 3868-3871
19. Robillard N., Wuillème S., Lodé L., et al. CD33 is expressed on plasma cells of a significant number of myeloma patients, and may represent a therapeutic target. Leukemia 19 (2005) 2021-2022
20. Went P., Agostinelli C., Gallamini A., et al. Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. J Clin Oncol 24 (2006) 2472-2479
21. Thieblemott C., and Coiffier B. Lymphoma in older patients. J Clin Oncol 25 (2007) 1916-1922
22. Enblad G., Hagberg H., Erlanson M., et al. A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood 203 (2004) 2920-2924
23. Qintanilla-Martinez L., Preffer F., Rubin D., et al. CD20+ T cell lymphoma, neoplastic transformation of a normal T cell subset. Am J Clin Pathol 102 (1994) 483-489
24. Takami A., Saito M., Nakao S., et al. CD20-positive T cell chronic lymphocytic leukemia. Br J Haematol 80 (1998) 1327-1329
25. Mohrmann R.L., and Arber D.A. CD20-positive peripheral T cell lymphoma: report of a case after nodular sclerosis Hodgkin's disease and review of the literature. Mod Pathol 13 (2000) 1244-1252
26. Yokose N., Ogata K., Sugisaki Y., et al. CD20-positive T cell leukemia/lymphoma. Ann Hematol 80 (2001) 372-375
27. Yao X., Teruya-Feldstein J., Raffeld M., et al. Peripheral T-cell lymphoma with aberrant expression of CD79a and CD20: a diagnostic pitfall. Mod Pathol 14 (2001) 105-110
28. Sun T., Akalin A., Rodacker M., et al. CD20 positive T cell lymphoma: is it a real entity?. J Clin Pathol 57 (2004) 442-444
29. Kitamura A., Yamashita Y., and Mori N. CD20-positive cytotoxic T cell lymphoma: report of two cases and review of the literature. J Clin Exp Hematopathol 45 (2005) 45-50
30. Magro C., Seilstad K., Porcu P., et al. Primary CD20+ CD10+ CD8+ T cell lymphoma of the skin with dual IgH and TCRβ gene rearrangement. Am J Clin Pathol 126 (2006) 14-22
31. Buckner C.L., Christiansen L.R., Bourgeois D., et al. CD20 positive T-cell lymphoma/leukemia: a rare entity with potential diagnostic pitfalls. Ann Clin Lab Sci 37 (2007) 263-267